IP Library Granted Patent US 9,816,074
Granted Patent B2
US 9,816,074 · App. 14/807,183 · Granted Nov 14, 2017

Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells

Inventors: Anthony Conway (Richmond, CA); Gregory J. Cost (Richmond, CA); Philip D. Gregory (Richmond, CA)
Assignee: Sangamo Therapeutics, Inc.
C12N5/0647A61K35/28C12N9/22C12N2500/38C12N2501/065C12N2501/2306C12N2501/999C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,816,074
App. No.
14/807,183
Granted
Nov 14, 2017
Kind
B2
Abstract

The present disclosure is in the field of genome engineering, particularly targeted modification of the genome of a hematopoietic stem cell.

Claims (14)

1. A cell culture comprising:

a stem cell comprising an exogenous nuclease that cleaves the genome of the stem cell;

interleukin 6 (IL-6);

lithium chlorine (LiCl); and

a histone deactylase inhibitor (HDACI), wherein the HDACI is valproic acid (VPA) at a concentration of between 1.25 and 5 mM.

2. The cell culture of claim 1 , wherein the stem cell further comprises a donor sequence.

3. A method for preparing a cell culture according to claim 1 , wherein the stem cells comprise exogenous nucleases that cleave the genomes of the stem cells, the method comprising

culturing the stem cells in the presence of the histone deactylase inhibitor (HDACI) wherein the HDACI is valproic acid (VPA) at a concentration of between 1.25 and 5 mM; interleukin 6 (IL-6); and lithium chlorine (LiCl).

4. The method of claim 3 , further comprising introducing one or more exogenous donor sequences into the stem cells such that the donor molecule is introduced into the genomes of the cells following cleavage by the nuclease.

5. The method of claim 3 , wherein the exogenous nucleases are delivered to the stem cells as a nucleic acid encoding the nuclease.

6. The method of claim 5 , wherein the nucleic acid is mRNA.

7. The method of claim 3 , wherein the exogenous nuclease is selected from the group consisting of a zinc finger nuclease (ZFN), a TALE-nuclease (TALEN), a CRISPR/Cas nuclease system or combinations thereof.

8. The method of claim 4 , wherein the donor sequences comprise a sequence selected from the group consisting of sequences encoding a protein, regulatory sequences, sequence that encode a structural nucleic acid such as a microRNA or siRNA.

9. The method of claim 8 , wherein the protein is selected from the group consisting of a regulatory protein that modulates expression of a gene; an antibody, an antigen, an enzyme, a growth factor, a receptor, a hormone, a lymphokine, a cytokine, a reporter and combinations thereof.

Assignments (2)
CHANGE OF NAME Recorded Sep 6, 2017
From: SANGAMO BIOSCIENCES, INC.
To: SANGAMO THERAPEUTICS, INC.
Reel/Frame 043772/0991 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 3, 2015
From: CONWAY, ANTHONY; COST, GREGORY J.; GREGORY, PHILIP D.
To: SANGAMO BIOSCIENCES, INC.
Reel/Frame 036237/0599 →
Continuity (4)
Provisional Application 62029002 · Jul 25, 2014
Provisional Application 62036454 · Aug 12, 2014
Provisional Application 62158257 · May 7, 2015
Related Publication 20160024474A1 · Jan 28, 2016